Abstract 141P
Background
The cultivation mode for tumor stem cells generally involves sorting. Fluorescence-activated cell sorting (FACS) and magnetic-activated cell sorting (MACS) are the main techniques for sorting CSCs. However, this is not the optimal solution. FACS is time-consuming, technically demanding, and yields a limited number of sorted cells. MACS, while operationally simple, can only sort one marker at a time. Conditional culture media require the addition of a large quantity of expensive growth factors. We established a dynamic suspension culture without additional sorting and cytokines to obtain cancer stem cell.
Methods
A dynamic suspension culture system without sorting and additional cytokines was used to obtain cancer stem cells. The immunostaining, RNA-seq, metabolomics and proteomics were performed to analyze the properties of cancer stem cells.
Results
The cancer stem cell was successfully cultivated from unconditionally dynamic suspension culture system. They exhibited the expression of specific cancer stem markers, such as upregulated CD44, CD133, ALDHA1, ABCB5 and decreased CD24.These cells possessed self-renewal capability and strong tumorigenicity. Meanwhile, their transcriptome, metabolism, proteins were reprogrammed. Drug metabolism cytochrome P450 and resistance to many drugs, such as platinum and methotrexate were activated. A metabolic switch from glycolysis to oxidative phosphorylation was founded in these cells. Importantly, actin cytoskeleton rearrangement and epithelial-mesenchymal transition were observed in these cells. The RNA-seq analyses show that signaling pathways, including HIF, Hippo and Wnt pathway were activated, resulting in the remodeling of cancer stem cell.
Conclusions
Independently sorting and the addition of cytokines, a dynamic suspension culture system can successfully generate cancer stem cells. These cells exhibited typical cancer stem cell properties, including reprogrammed transcriptome, metabolism, and protein levels. This unconditional dynamic suspension culture system offers an alternative method for cultivating cancer stem cells and presents a novel model for exploring their characteristics.
Editorial acknowledgement
Clinical trial identification
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
163TiP - Single-institution, single-arm, open-label phase II basket study of mutation and/or elevated hedgehog (Hh) expression-directed smoothened inhibitor sonidegib in patients with advanced solid malignancies
Presenter: Madhawa De Silva
Session: Cocktail & Poster Display session
Resources:
Abstract
164TiP - MONSTAR-GLYCO: A multi-institutional prospective study harnessing glycomics and multi-omics on the j-glyconet and SCRUM-MONSTR platform
Presenter: Tadayoshi Hashimoto
Session: Cocktail & Poster Display session
Resources:
Abstract
166P - Unravelling HR-positive, HER2-negative breast cancer and its tumor microenvironment heterogeneity using spatial transcriptomics
Presenter: Bengisu Karakose
Session: Cocktail & Poster Display session
Resources:
Abstract
167P - Cancer neutrophil encyclopedia: A deep dive into antigen-presenting warriors
Presenter: Yingcheng Wu
Session: Cocktail & Poster Display session
Resources:
Abstract
168P - Tumor microenvironment (TME) and PD-L1 expression heterogeneity in high grade serous ovarian cancer (HGSC) samples analysis from the randomized NeoPembrOV/GINECO phase II trial
Presenter: Laetitia Collet
Session: Cocktail & Poster Display session
Resources:
Abstract
169P - Tumour microenvironment in glioblastoma: A single-cell perspective on macrophage dynamics and T cell exhaustion
Presenter: Farasat Kazmi
Session: Cocktail & Poster Display session
Resources:
Abstract
170P - Digital spatial profiling to uncover biomarkers for response prediction in locally advanced gastric cancer patients treated with neoadjuvant chemotherapy
Presenter: Chiara Molinari
Session: Cocktail & Poster Display session
Resources:
Abstract
171P - Immune-modulatory drug profiling using perfused, microfluidic on-chip co-cultures of patient-derived ovarian cancer microtumors and autologous immune cells
Presenter: Sarah Plöger
Session: Cocktail & Poster Display session
Resources:
Abstract
172P - The impact of androgen ablation on the immune landscape in therapy-resistant prostate cancer: Insights from tumour microenvironment analysis
Presenter: Jodi Stewart
Session: Cocktail & Poster Display session
Resources:
Abstract
173P - NRF2 levels in high grade serous ovarian cancer: Characterization and treatment
Presenter: Helen Toma
Session: Cocktail & Poster Display session
Resources:
Abstract